Cenix

NEW YORK (GenomeWeb) – Cenix BioScience this week announced it has signed an agreement to provide target-validation services to BASF company Metanomics.

NEW YORK (GenomeWeb) – Cenix Biosciences this week announced that it has signed an agreement to provide RNAi-based high-content screening services to Germany's Bayer Pharma.

Cenix BioScience this week announced that it has signed an agreement to provide its research services to Swiss drugmaker Debiopharm.

Cenix BioScience said this week that its roughly one-year old service contract with Ugichem, a developer of novel gene-silencing therapeutics, has been extended.

The company has added respiratory and inflammation to an RNAi screening program that began with oncology.

The company, which until recently has focused almost exclusively "on cell-based work," expects that the delivery technology will facilitate its in vivo work and enable RNAi-based therapeutics.

The company will use RNAi technologies for cell-based screens for cancer drugs.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.